Supriya Lifescience
Market cap ₹4,948 Cr
- P/E
- 27.93
- Day range
- ₹610.80 – ₹620.95
- 52-week range
- ₹545.50 – ₹1,085.00
- Volume
- 1.93 L
- Open
- ₹616.20
- Prev close
- ₹620.65
Latest results · Q2 FY27(standalone)Revenue ₹206 Cr+3.2%Profit ₹29 Cr-42.0%Margin 14.2%YoY vs the same quarter last year
1 red flag to read up on
- high
Under Additional surveillance (ASM)
The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
SUPRIYA in NSE indices and F&O
Research profile
Composite 50 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.6%
- 12-1 mom.
- +17.2%
- Return / vol
- -0.37
- Magic Formula
- #129
- FCF yield
- 0.7%
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Supriya LifescienceSUPRIYA | ₹4,948 Cr | 27.93 | — | 19.0% | 25.0% | 22.0% | 0.00 | +3.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 21h agoHeadlines about Supriya Lifescience from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- ROE (FY26)
- 19.0%
- ROCE (latest year)
- 25%
Moving averages (NSE)
- 20-day
- ₹762.88
- Price below
- 50-day
- ₹851.81
- Price below
- 200-day
- ₹783.71
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 | 206 |
| YoY Sales growth | — | — | — | — | — | — | -10 | — | — | — | — | — |
| Expenses | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 | 161 |
| Operating Profit | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 | 45 |
| OPM % | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% | 22% |
| Other Income | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
| Interest | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 | 9 |
| Profit before tax | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 | 38 |
| Tax % | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% | 23% |
| Net Profit | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 | 29 |
| EPS in Rs | ₹3.70 | ₹4.59 | ₹5.55 | ₹5.73 | ₹5.81 | ₹6.26 | ₹4.32 | ₹6.27 | ₹6.17 | ₹9.22 | ₹2.99 | ₹3.63 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+28 days since Mar 2021 (S)
+23 days since Mar 2021 (S)
+14 days since Mar 2021 (S)
+37 days since Mar 2021 (S)
+119 days since Mar 2021 (S)
Strengths, risks & growth
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 68.30% | 68.30% | 68.30% | 68.30% | 0.00 pp |
| FII | 5.19% | 5.16% | 6.18% | 6.45% | +0.27 pp |
| DII | 5.00% | 5.70% | 5.30% | 5.47% | +0.17 pp |
| Public | 21.49% | 20.83% | 20.21% | 19.80% | -0.41 pp |
Filed with NSE for Sept 2026: promoters 68.30%, public 31.70%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 1.28% (-0.01 pp)- Promoters68.3%
- Foreign institutions6.4%
- Mutual funds1.3%
- Insurance2.4%
- Other domestic institutions1.8%
- Retail14.2%
- Others5.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Abakkus Flexi Cap Fund | 0.88% | 0.56% | -0.18 pp |
| ITI Large & Mid Cap Fund | 0.21% | 1.49% | -0.01 pp |
| Quantum Small Cap Fund | 0.18% | 3.75% | +0.12 pp |
| ITI ELSS Tax Saver Fund | 0.15% | 1.87% | +0.13 pp |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.12% | 0.27% | +0.02 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 51.1%
- Downside volatility
- 53.8%
- Worst 5% of days
- 4.2%
- Average of that tail
- 8.1%
- Max drawdown (1Y)
- 41.6%
- Below its peak
- 41.6%
Against the market
- Beta vs Nifty 50
- 0.49
- Correlation
- 0.13
- Relative strength (3M)
- -25.5%
- ATR (14)
- 5.9%
Return
- Return 1M
- -30.6%
- Return 3M
- -21.6%
- Return 6M
- -10.1%
- Return 1Y
- -18.7%
- vs 200-day average
- -21.6%
Momentum
- RSI (14) · oversold
- 23.3
- MACD histogram
- -18.09
- Stochastic %K
- 5.9
- ADX (14)
- 33.8
- +DI / −DI
- 11.3 / 46.0
- Money flow index
- 15.2
Participation
- Delivery (20d avg)
- 44.3%
- vs its 60-day baseline
- +1.1 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.0%
- 52-week position
- 12 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- ₹34 Cr
- FCF yield
- 0.7%
- Net debt
- -₹35 Cr
- Net debt / equity
- -0.03
- EV / sales
- 5.64
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
4 Sept 2026ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
4 Sept 2025ex-date - dividend₹0.80
Annual General Meeting/Dividend - Rs 0.80 Per Share
20 Sept 2024ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.60 Per Share
15 Sept 2023ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.60 Per Share
1 Sept 2022ex-date
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 6 Mar from icra
- Rating update · 30 Dec 2025 from fitch
- Rating update · 6 Feb 2025 from icra
- Rating update · 10 Nov 2023 from icra
- Rating update · 26 Sep 2022 from icra
- Rating update · 26 Jul 2021 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Supriya Lifescience: common questions
Answered from the figures on this page.